604
Participants
Start Date
February 28, 2011
Primary Completion Date
December 31, 2012
Study Completion Date
February 20, 2013
AN2690 Topical Solution, 5%
AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Solution Vehicle
AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Investigational Site, Philadelphia
Investigational Site, Harrisonburg
Investigational Site, Norfolk
Investigational Site, High Point
Investigational Site, Raleigh
Investigational Site, Greer
Investigational Site, Miami
Investigational Site, Miami
Investigational Site, Knoxville
Investigational Site, Columbus
Investigational Site, Evansville
Investigational Site, Ann Arbor
Investigational Site, St Louis
Investigational Site, Dallas
Investigational Site, San Antonio
Investigational Site, Nampa
Investigational Site, Salt Lake City
Investigational Site, Phoenix
Investigational Site, Albuquerque
Investigational Site, Oceanside
Investigational Site, San Diego
Investigational Site, San Francisco
Investigational Site, Novato
Investigational Site, Santa Rosa
Investigational Site, Portland
Investigational Site, Verona
Investigational Site, Barrie
Investigational Site, Markham
Investigational Site, North Bay
Investigational Site, Boucherville
Investigational Site, Montreal
Investigational Site, Québec
Lead Sponsor
Pfizer
INDUSTRY